From our study, we can presume that PARP-1 inhibitor resistant tumours could have higher OXPHOS and nucleolar protein pools, which would be exciting targets for the combinatorial strategy to deal with such therapy-resistant tumours. This evidence concerns the gene PARP1 and neoplasm.